Download Full Volume - United States Renal Data System

More documents

Recommendations

Info

AINCIDENCE OF REPORTED ESRD Reference section A 284 A.1 . 285 Incident counts of reported ESRD: all patients by demographic characteristics & primary diagnosis A.2 . 289 Incident rates of reported ESRD per million population, by demographic characteristics & primary diagnosis A.3 . 293 Incident rates of reported diabetic ESRD per million population, by demographic characteristics A.4 . 295 Incident counts of reported ESRD patients, 2001-2003 by age, gender, & race A.5 . 296 Incident rates of reported ESRD, 2001-2003 per million population, by age, gender, & race A.6 . 297 Mean age at start of ESRD therapy by demographic characteristics & primary diagnosis A.7 . 299 Incidence of reported ESRD, by primary diagnosis: all patients 1999-2003 combined, by detailed primary diagnosis A.8 . 301 Incident counts of reported ESRD patients, by diabetic status & state/territory A.9 . 307 Incident rates of reported ESRD, by diabetic status & state, adjusted per million population A.10 . 313 Incident counts of reported ESRD patients, by diabetic status & ESRD network A.11 . 315 Incident rates of reported ESRD, by diabetic status & ESRD network, adjusted per million population
ON OUR WEBSITE & CD Incident counts of reported ESRD, by primary diagnosis, (A.1.1-4), patients residing in Puerto Rico & U.S. territories (A.a). INCIDENCE OF REPORTED ESRD 2005 Annual <strong>Data</strong> ReportA Table A.1 Incident counts of reported ESRD: all patients by demographic characteristics & primary diagnosis 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 0-4 47 69 101 106 112 139 136 148 145 158 151 182 5-9 97 97 105 88 110 103 122 115 106 131 154 129 10-14 179 188 224 211 230 217 213 220 225 208 249 248 15-19 433 476 456 444 431 442 457 484 522 526 548 490 20-29 1,540 1,689 1,902 1,857 2,007 2,088 2,159 2,186 2,420 2,584 2,637 2,651 30-39 2,222 2,484 2,768 2,851 3,077 3,313 3,673 3,834 4,297 4,652 4,893 5,149 40-49 2,447 2,741 2,890 3,250 3,389 3,703 4,002 4,523 5,018 5,690 6,280 7,003 50-59 3,759 4,375 4,690 4,853 5,129 5,510 5,813 6,290 7,206 7,733 8,362 9,016 60-64 2,139 2,464 2,791 3,223 3,533 3,959 4,146 4,621 5,072 5,527 6,145 6,702 65-69 2,187 2,273 2,602 3,335 3,522 3,934 4,460 5,117 5,670 6,544 7,254 8,034 70-79 2,533 2,754 3,404 4,690 4,933 5,796 6,607 7,463 8,317 9,792 10,886 12,697 80+ 434 491 646 1,017 1,099 1,383 1,669 1,944 2,289 2,907 3,359 3,869 Unknown . * * * * 17 14 * * * * * 0-19 756 830 886 849 883 901 928 967 998 1,023 1,102 1,049 20-44 4,877 5,471 6,024 6,226 6,654 7,151 7,736 8,209 9,137 9,905 10,651 11,215 45-64 7,230 8,282 9,017 9,808 10,481 11,422 12,057 13,245 14,876 16,281 17,666 19,306 65-74 3,795 4,024 4,764 6,208 6,462 7,427 8,291 9,488 10,451 12,067 13,528 15,322 75+ 1,359 1,494 1,888 2,834 3,092 3,686 4,445 5,036 5,825 7,176 7,971 9,278 Unknown . * * * * 17 14 * * * * * 285 Male 10,041 11,124 12,437 14,222 15,220 16,590 18,267 20,004 22,154 25,026 27,344 29,991 Female 7,976 8,977 10,150 11,711 12,360 14,010 15,203 16,946 19,137 21,436 23,582 26,180 Unknown . * . * * * * * * . . * White 12,593 14,004 15,753 17,675 18,829 20,857 22,909 25,003 27,483 30,886 33,876 37,231 Black 4,876 5,508 6,203 7,476 7,892 8,744 9,415 10,664 12,175 13,913 15,016 16,697 Native American 122 144 186 275 286 300 372 424 507 545 596 641 Asian 110 179 357 373 466 591 631 736 911 1,009 1,279 1,449 Other/unknown 316 267 88 136 108 112 144 124 216 109 159 155 †Hispanic †Non-Hispanic Diabetes 2,690 4,043 5,308 6,218 7,513 8,708 10,092 11,477 13,072 15,770 18,138 20,720 Hypertension 3,141 4,528 5,838 6,349 7,152 8,241 8,924 10,342 11,937 13,878 15,301 16,982 Glomerulonephritis 2,802 3,633 4,265 4,493 4,816 5,089 5,353 5,854 6,234 6,610 7,053 7,262 Cystic kidney 765 944 1,081 1,105 1,148 1,228 1,311 1,362 1,400 1,417 1,573 1,624 Other urologic 483 679 874 968 985 1,184 1,214 1,341 1,389 1,405 1,331 1,494 Other cause 1,781 2,227 2,827 3,134 3,343 3,608 3,708 3,729 3,890 4,455 4,646 5,009 Unknown cause 1,625 1,679 1,414 1,457 1,495 1,588 1,832 2,021 2,242 2,149 2,287 2,554 Missing disease 4,730 2,369 980 2,211 1,129 958 1,037 825 1,128 778 597 528 U.S. 17,555 19,638 22,055 25,379 26,948 29,904 32,728 36,179 40,283 45,431 49,863 55,119 U.S territories * 16 18 19 14 30 28 35 47 51 59 69 Puerto Rico 235 245 299 300 377 387 403 425 489 576 583 665 Foreign * 14 * 13 13 20 13 15 19 20 43 38 Unknown 209 189 207 224 229 263 299 297 454 384 378 282 All 18,017 20,102 22,587 25,935 27,581 30,604 33,471 36,951 41,292 46,462 50,926 56,173 The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule. The age of the incident patient is determined as of the date of ESRD initiation. †CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank. *Values for cells with 10 or fewer patients are suppressed. "." Zero values in this cell.
Page 1: Reference A Section Incidence of re
Page 5 and 6: INCIDENCE OF REPORTED ESRD 2005 Ann
Page 7 and 8: ON OUR WEBSITE & CD Incident rates
Page 13 and 14: ON OUR WEBSITE & CD Incident counts
Page 15 and 16: ON OUR WEBSITE & CD Median age at s
Page 17 and 18: ON OUR WEBSITE & CD Incidence of re
Page 21 and 22: Table A.8 A.8 (continued) Incident
Page 35 and 36: Reference B Section Prevalence of r
Page 37 and 38: ON OUR WEBSITE & CD Point prevalent
Page 39 and 40: Table B.1 B.1 (continued) Point pre
Page 43 and 44: Table B.2 B.2 (continued) Point pre
Page 45 and 46: PREVALENCE OF REPORTED ESRD 2005 An
Page 49 and 50: ON OUR WEBSITE & CD Median age at s
Page 51 and 52: ON OUR WEBSITE & CD Prevalence of r
Page 53 and 54:
ON OUR WEBSITE & CD Point prevalent
Page 55 and 56:
Table B.8 B.8 (continued) PREVALENC
Page 57 and 58:
Table B.8 B.8 (continued) PREVALENC
Page 59 and 60:
Table B.9 B.9 Point prevalent rates
Page 61 and 62:
Table B.9 B.9 (continued) Point pre
Page 63 and 64:
Table B.9 B.9 (continued) Point pre
Page 65 and 66:
ON OUR WEBSITE & CD Point prevalent
Page 67 and 68:
Table B.11 B.11 Point prevalent rat
Page 69 and 70:
PREVALENCE OF REPORTED ESRD 2005 An
Page 71 and 72:
Reference C Section Patient charact
Page 73 and 74:
PATIENT CHARACTERISTICS 2005 Annual
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
ON OUR WEBSITE & CD Mean eGFR by MD
Page 85 and 86:
Table C.14 C.14 Percent distributio
Page 87 and 88:
Reference D Section Treatment modal
Page 89 and 90:
TREATMENT MODALITIES 2005 Annual Da
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
ON OUR WEBSITE & CD Incident ESRD p
Page 109 and 110:
ON OUR WEBSITE & CD Treatment statu
Page 111 and 112:
Page 113 and 114:
ON OUR WEBSITE & CD Living ESRD pat
Page 115 and 116:
Reference E Section Transplantation
Page 117 and 118:
TRANSPLANTATION: 2005 Annual Data P
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
ON OUR WEBSITE & CD Median time in
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
ON OUR WEBSITE & CD Renal transplan
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Reference F Section Transplantation
Page 141 and 142:
ON OUR WEBSITE & CD 90-day death-ce
Page 143 and 144:
ON OUR WEBSITE & CD One-year death-
Page 145 and 146:
ON OUR WEBSITE & CD Two-year death-
Page 147 and 148:
ON OUR WEBSITE & CD Three-year deat
Page 149 and 150:
ON OUR WEBSITE & CD Five-year death
Page 151 and 152:
ON OUR WEBSITE & CD Ten-year graft
Page 153 and 154:
TRANSPLANTATION: 2005 Annual OUTCOM
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Table F.13 F.13 90-day survival wit
Page 165 and 166:
Table Table F.14 F.14 One-year surv
Page 167 and 168:
Page 169 and 170:
Table F.16 F.16 Three-year survival
Page 171 and 172:
Table Table F.17 F.17 Five-year sur
Page 173 and 174:
Table F.18 F.18 Ten-year survival w
Page 175 and 176:
Page 177 and 178:
Table F.20 F.20 (continued) One-yea
Page 179 and 180:
Table F.21 F.21 (continued) Two-yea
Page 181 and 182:
Table Table F.22 F.22 (continued) (
Page 183 and 184:
Table F.23 F.23 (continued) Five-ye
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Reference G Section Morbidity & hos
Page 195 and 196:
ON OUR WEBSITE & CD jkfj Total admi
Page 197 and 198:
ON OUR WEBSITE & CD Total admission
Page 199 and 200:
ON OUR WEBSITE & CD Total admission
Page 201 and 202:
ON OUR WEBSITE & CD Hospital days p
Page 203 and 204:
ON OUR WEBSITE & CD Hospital days p
Page 205 and 206:
Table G.11 G.11 Inpatient utilizati
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
MORBIDITY & 2005 HOSPITALIZATIONG A
Page 213 and 214:
MORBIDITY & 2005 HOSPITALIZATIONG A
Page 215 and 216:
Reference H Section Mortality & cau
Page 217 and 218:
MORTALITY & CAUSES OF DEATH 2005 An
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Table H.6 H.6 (continued) Annual mo
Page 233 and 234:
Page 235 and 236:
Table H.8 H.8 (continued) Annual mo
Page 237 and 238:
Page 239 and 240:
Table H.10 H.10 (continued) Annual
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
Page 249 and 250:
Table H.16 H.16 Annual mortality ra
Page 251 and 252:
Table H.17 H.17 (continued) Total p
Page 253 and 254:
Table H.18 H.18 (continued) MORTALI
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Table H.24 H.24 Annual mortality ra
Page 265 and 266:
Page 267 and 268:
Table H.26 H.26 (continued) MORTALI
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
ON OUR WEBSITE & CD Mortality rates
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Reference I Section Patient surviva
Page 295 and 296:
I PATIENT SURVIVAL 2005 Annual Data
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Table I.8 (continued) Table Inciden
Page 313 and 314:
Page 315 and 316:
Page 317 and 318:
Page 319 and 320:
Page 321 and 322:
Page 323 and 324:
Page 325 and 326:
Page 327 and 328:
Page 329 and 330:
Page 331 and 332:
Page 333 and 334:
Page 335 and 336:
Page 337 and 338:
Page 339 and 340:
Page 341 and 342:
Page 343 and 344:
Page 345 and 346:
Page 347 and 348:
Page 349 and 350:
Page 351 and 352:
Page 353 and 354:
Page 355 and 356:
Page 357 and 358:
Page 359 and 360:
Page 361 and 362:
Page 363 and 364:
Page 365 and 366:
Page 367 and 368:
Page 369 and 370:
Page 371 and 372:
Reference J Section Provider charac
Page 373 and 374:
Table J.1 J.1 Certified dialysis &
Page 375 and 376:
Table J.5 J.5 Dialysis & transplant
Page 377 and 378:
PROVIDER CHARACTERISTICS 2005 Annua
Page 379 and 380:
Table J.13 J.13 Dialysis patients:
Page 381 and 382:
PROVIDER CHARACTERISTICS JReference
Page 383 and 384:
Reference K Section Medicare costs
Page 385 and 386:
Table K.1 K.1 Total Medicare costs
Page 387 and 388:
MEDICARE COSTS FOR ESRD 2005 Annual
Page 389 and 390:
Page 391 and 392:
Page 393 and 394:
Page 395 and 396:
Page 397 and 398:
Page 399 and 400:
Page 401 and 402:
Reference L Section Vascular access
Page 403 and 404:
Table L.1 L.1 Catheter insertions i
Page 405 and 406:
Table L.3 L.3 Graft insertions in p
Page 407 and 408:
VASCULAR 2005 Annual Data ACCESSL R
Page 409 and 410:
Page 411 and 412:
Page 413 and 414:
Page 415 and 416:
Page 417 and 418:
Page 419 and 420:
Page 421 and 422:
Table L.12 L.12 Arteriovenous fistu
Page 423 and 424:
Reference M Section Census populati
Page 425 and 426:
CENSUS POPULATIONS 2005 Annual Data
Page 427 and 428:
Page 429 and 430:
Page 431 and 432:
Page 433 and 434:
Table M.2 M.2 Resident population e
show all

Download Full Volume - United States Renal Data System

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?